NO20071653L - Krystallinske former av en pyrazolo'3,4-C pyridin faktor XA inhibitor. - Google Patents

Krystallinske former av en pyrazolo'3,4-C pyridin faktor XA inhibitor.

Info

Publication number
NO20071653L
NO20071653L NO20071653A NO20071653A NO20071653L NO 20071653 L NO20071653 L NO 20071653L NO 20071653 A NO20071653 A NO 20071653A NO 20071653 A NO20071653 A NO 20071653A NO 20071653 L NO20071653 L NO 20071653L
Authority
NO
Norway
Prior art keywords
crystalline forms
pyrazolo
pyridine
inhibitor
factor
Prior art date
Application number
NO20071653A
Other languages
English (en)
Inventor
Bang-Chi Chen
Mary F Malley
Huiping Zhang
Margaret M Gleeson
Gary Mcgeorge
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36100111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071653(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20071653L publication Critical patent/NO20071653L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer krystallinske former av l-(3-klorfenyl)-7-okso-6-[4-(2-okso-l(2H)pyridinyl)fenyl]-4,5,6,7-tetrahydro-l/H-pyrazolo[3,4-c]pyridin-3-karboksamid og solvater derav; fremgangsmåter for fremstilling av slike krystallinske former; farmasøytiske preparater omfattende slike krystallinske former; og metoder for behandling av tromboemboliské lidelser med slike krystallinske former eller slike farmasøytiske preparater.
NO20071653A 2004-09-28 2007-03-28 Krystallinske former av en pyrazolo'3,4-C pyridin faktor XA inhibitor. NO20071653L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61365604P 2004-09-28 2004-09-28
US11/235,519 US7388096B2 (en) 2004-09-28 2005-09-26 Crystalline forms of a factor Xa inhibitor
PCT/US2005/034512 WO2006036927A1 (en) 2004-09-28 2005-09-27 Crytalline forms of a pyrazolo `3, 4-c ! pyridine factor xa inhibitor

Publications (1)

Publication Number Publication Date
NO20071653L true NO20071653L (no) 2007-03-30

Family

ID=36100111

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071653A NO20071653L (no) 2004-09-28 2007-03-28 Krystallinske former av en pyrazolo'3,4-C pyridin faktor XA inhibitor.

Country Status (12)

Country Link
US (1) US7388096B2 (no)
EP (1) EP1819703A1 (no)
JP (1) JP2008514711A (no)
KR (1) KR20070067108A (no)
AU (1) AU2005289599A1 (no)
BR (1) BRPI0516171A (no)
CA (1) CA2582223A1 (no)
IL (1) IL182148A0 (no)
MX (1) MX2007003426A (no)
NO (1) NO20071653L (no)
RU (1) RU2007115859A (no)
WO (1) WO2006036927A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304157B2 (en) 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
RU2007126770A (ru) * 2004-12-15 2009-01-27 Бристол-Маерс Сквибб Компани (Us) Кристаллические формы ингибитора фактора ха
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
CA2959987C (en) * 2014-09-02 2023-05-09 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Pyrazolo[3,4-c]pyridine compounds and their anti-thrombosis effect

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2345993C2 (ru) 2001-09-21 2009-02-10 Бристол-Маерс Сквибб Компани ЛАКТАМСОДЕРЖАЩЕЕ СОЕДИНЕНИЕ И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Also Published As

Publication number Publication date
AU2005289599A1 (en) 2006-04-06
US20060069118A1 (en) 2006-03-30
WO2006036927A1 (en) 2006-04-06
MX2007003426A (es) 2007-05-10
IL182148A0 (en) 2007-07-24
JP2008514711A (ja) 2008-05-08
RU2007115859A (ru) 2008-11-10
KR20070067108A (ko) 2007-06-27
CA2582223A1 (en) 2006-04-06
BRPI0516171A (pt) 2008-08-26
US7388096B2 (en) 2008-06-17
EP1819703A1 (en) 2007-08-22

Similar Documents

Publication Publication Date Title
CL2008002717A1 (es) 3-(1-clorofenil)-7-oxo-6-[4-(2-oxo-1(2h)piridinil)fenil]-4,5,6,7-tetrahidro-1h-pirazolo[3,4-c]piridin-3-carboxamida y 3-(1-hidroxi-1-metil-etil)-1-(a-metoxi-fenil)-6-[4-(2-oxo-2h-piridin-1-il)-fenil]-1,4,5,6-tetrahidro-pirazolo[3,4-c]piridin-7-ona; composicion farmaceutica; combinacion farmaceutica y uso en el tratamiento de un desorden tromboembolico
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
NO20064000L (no) Heteroarylkoblede pyrazoloderivater
WO2002087513A3 (en) Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
AP1767A (en) 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
NO20066055L (no) Pyridinderivater
NO20045461L (no) Nye pyridazin 3-(2H)-on derivater som PDE4-inhibitorer
NO20053046L (no) 4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer.
NO20061454L (no) Compounds having CRTH2 antagonist activity
WO2000035886A3 (en) (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
NO20082065L (no) Nye imidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase 3 for anvendelse ved behandling av demens og neurodegenerative forstyrrelser
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
WO2005095409A3 (en) Tetrahydroquinoline derivatives and a process for preparing the same
NO20064015L (no) Kondenserte derivater av pyrazol
WO2007013896A3 (en) Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
WO2004043337A3 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
MY138737A (en) N3-substituted imidazopyridine c-kit inhibitors
NO20071653L (no) Krystallinske former av en pyrazolo'3,4-C pyridin faktor XA inhibitor.
NO20071634L (no) Effektiv syntese av 4,5-dihydro-pyrazolo(3,4-C)pyrid-2-oner
AU2002356251A1 (en) 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo-(3.2.2)nonane derivatives, preparation and therapeutic use thereof
MXPA03001356A (es) Nuevos agentes inhibidores de beta-amiloides, procedimientos para su preparacion y su uso como medicamentos.
NO20072666L (no) Krystallinske former av en faktor Xa-inhibitor
EP1736155A4 (en) MEDICAMENT COMPRISING A COMBINATION OF AN ACETYLCHOLINE ESTERASE INHIBITOR AND A SUBSTITUTED 3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2 (1H) -ONE DERIVATIVE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application